CH675593A5 - - Google Patents

Download PDF

Info

Publication number: CH675593A5
Authority: CH; Switzerland
Prior art keywords: fragment; hind iii; gene; test; sample
Prior art date: 1986-02-27

Application number

CH756/87A

Other languages

German (de)

English (en)

Inventor

Marjut Ranki

Hans Soederlund

Original Assignee

Orion Yhtymae Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-02-27

Filing date

1987-02-26

Publication date

1990-10-15

1987-02-26 Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy

1990-10-15 Publication of CH675593A5 publication Critical patent/CH675593A5/de

Links

238000012360 testing method Methods 0.000 claims abstract description 82
150000007523 nucleic acids Chemical class 0.000 claims abstract description 80
108020004707 nucleic acids Proteins 0.000 claims abstract description 79
102000039446 nucleic acids Human genes 0.000 claims abstract description 79
238000000034 method Methods 0.000 claims abstract description 47
238000009396 hybridization Methods 0.000 claims abstract description 40
108090000623 proteins and genes Proteins 0.000 claims abstract description 36
108020004999 messenger RNA Proteins 0.000 claims abstract description 19
230000003321 amplification Effects 0.000 claims abstract description 12
238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 12
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
239000012634 fragment Substances 0.000 claims description 66
239000013612 plasmid Substances 0.000 claims description 42
108020004414 DNA Proteins 0.000 claims description 35
239000013598 vector Substances 0.000 claims description 20
108700024542 myc Genes Proteins 0.000 claims description 12
108090000157 Metallothionein Proteins 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
108700020796 Oncogene Proteins 0.000 claims description 8
101150074155 DHFR gene Proteins 0.000 claims description 7
102000053602 DNA Human genes 0.000 claims description 7
101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 7
102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 7
101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 7
239000003550 marker Substances 0.000 claims description 7
238000011144 upstream manufacturing Methods 0.000 claims description 7
241000713333 Mouse mammary tumor virus Species 0.000 claims description 6
101150017040 I gene Proteins 0.000 claims description 5
108010022394 Threonine synthase Proteins 0.000 claims description 5
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 claims description 4
229920002477 rna polymer Polymers 0.000 claims description 4
108700039691 Genetic Promoter Regions Proteins 0.000 claims description 3
101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 3
238000002955 isolation Methods 0.000 claims 1
238000011002 quantification Methods 0.000 abstract 1
239000000523 sample Substances 0.000 description 59
210000004027 cell Anatomy 0.000 description 50
102100024746 Dihydrofolate reductase Human genes 0.000 description 17
239000000243 solution Substances 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
239000000020 Nitrocellulose Substances 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
229920001220 nitrocellulos Polymers 0.000 description 8
238000013519 translation Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
101150026150 mt gene Proteins 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
238000012270 DNA recombination Methods 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
102000052708 Recessive Genes Human genes 0.000 description 2
108700005079 Recessive Genes Proteins 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012488 sample solution Substances 0.000 description 2
108010051423 streptavidin-agarose Proteins 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
102100030708 GTPase KRas Human genes 0.000 description 1
101710113436 GTPase KRas Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
238000010411 cooking Methods 0.000 description 1
229940119679 deoxyribonucleases Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229940094991 herring sperm dna Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
238000003793 prenatal diagnosis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CH756/87A 1986-02-27 1987-02-26 CH675593A5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FI860836A FI76119C (fi)	1986-02-27	1986-02-27	Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.

Publications (1)

Publication Number	Publication Date
CH675593A5 true CH675593A5 (fr)	1990-10-15

Family

ID=8522222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH756/87A CH675593A5 (fr)	1986-02-27	1987-02-26

Country Status (26)

Country	Link
JP (1)	JPS62205800A (fr)
KR (1)	KR870008033A (fr)
AT (1)	AT393511B (fr)
AU (1)	AU603562B2 (fr)
BE (1)	BE1001168A4 (fr)
CA (1)	CA1287558C (fr)
CH (1)	CH675593A5 (fr)
DD (1)	DD270383A5 (fr)
DE (1)	DE3706285A1 (fr)
DK (1)	DK174784B1 (fr)
ES (1)	ES2061411A6 (fr)
FI (1)	FI76119C (fr)
FR (1)	FR2594849B1 (fr)
GB (1)	GB2187283B (fr)
HU (1)	HU201808B (fr)
IE (1)	IE66904B1 (fr)
IL (1)	IL81695A (fr)
IS (1)	IS3197A7 (fr)
IT (1)	IT1202581B (fr)
LU (1)	LU86792A1 (fr)
NL (1)	NL195097C (fr)
NO (1)	NO175380C (fr)
NZ (1)	NZ219421A (fr)
PT (1)	PT84368B (fr)
SE (1)	SE468816B (fr)
ZA (1)	ZA871401B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714380A (en)	1986-10-23	1998-02-03	Amoco Corporation	Closed vessel for isolating target molecules and for performing amplification
IL86724A (en)	1987-06-19	1995-01-24	Siska Diagnostics Inc	Methods and kits for amplification and testing of nucleic acid sequences
EP0304845A3 (fr) *	1987-08-28	1991-03-06	Profile Diagnostic Sciences Inc.	Procédé et composition pour déterminer l'expression des gènes
DE68921918T2 (de) *	1988-05-09	1995-09-07	Univ Temple	Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.
AU629845B2 (en) *	1988-08-30	1992-10-15	Abbott Laboratories	Detection and amplification of target nucleic acid sequences
WO1990014440A1 (fr) *	1989-05-18	1990-11-29	The United States Of America, Represented By The Secretary, United States Department Of Commerce	SONDE ARN POUR LA DETECTION DE ARNm c-fes
US5232829A (en) *	1989-09-29	1993-08-03	Hoffmann-La Roche Inc.	Detection of chlamydia trachomatis by polymerase chain reaction using biotin labelled lina primers and capture probes
DK138090D0 (da) *	1990-06-06	1990-06-06	Novo Nordisk As	Diagnostisk analysemetode
EP0534640B1 (fr) *	1991-09-23	1996-10-02	Pfizer Inc.	Procédé pour détecter ARNm et ADN spécifiques dans les cellules
US6300058B1 (en)	1992-01-29	2001-10-09	Hitachi Chemical Research Center, Inc.	Method for measuring messenger RNA
GB9210916D0 (en) *	1992-05-21	1992-07-08	Isis Innovation	Nucleic acid quantification
US5580971A (en) *	1992-07-28	1996-12-03	Hitachi Chemical Company, Ltd.	Fungal detection system based on rRNA probes
WO1994002636A1 (fr) *	1992-07-28	1994-02-03	Hitachi Chemical Company Ltd.	Systeme de detection de gene
ES2055661B1 (es) *	1993-01-20	1995-03-01	Univ Malaga	Determinacion de la expresion genica por captura especifica de arn y su cuantificacion directa por electroforesis capilar en zona libre.
GB9309966D0 (en) *	1993-05-14	1993-06-30	Nordion Int Inc	Detection of prostrate-specific antigen in breast tumors
GB9415489D0 (en) *	1994-08-01	1994-09-21	Nordion Int Inc	Detection of prostate-specific antigen in amniotic fluid
AT401062B (de) *	1994-09-26	1996-06-25	Immuno Ag	Verfahren zur quantifizierung von nukleinsäuren
CN102822352B (zh)	2010-03-31	2015-07-29	有限会社山口技术特许机构	利用核酸色谱法的肺炎病原菌的检出方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4442203A (en) *	1981-06-30	1984-04-10	Massachusetts Institute Of Technology	Gene amplification assay for detecting tumor promoters
FI63596C (fi) *	1981-10-16	1983-07-11	Orion Yhtymae Oy	Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
EP0103632B1 (fr) *	1982-03-15	1990-12-19	The Trustees Of Columbia University In The City Of New York	Procede d'introduction de genes clones, amplifiables, dans des cellules eucaryotes et de production de produits proteiniques
IE56509B1 (en) *	1982-11-04	1991-08-28	Univ California	Methods for oncogenic detection
FI71768C (fi) *	1984-02-17	1987-02-09	Orion Yhtymae Oy	Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning.
US4675283A (en) *	1984-07-19	1987-06-23	Massachusetts Institute Of Technology	Detection and isolation of homologous, repeated and amplified nucleic acid sequences
FI72146C (fi) *	1985-01-02	1987-04-13	Orion Yhtymae Oy	Foerfarande foer identifiering av nukleinsyror.
FR2583771B1 (fr) *	1985-06-21	1988-12-09	Centre Nat Rech Scient	Sequences d'adn d'archaebacteries homologues a l'oncogene v-myc, proteines codees par ces sequences, leurs procedes d'obtention et leurs applications immunologiques

1986
- 1986-02-27 FI FI860836A patent/FI76119C/fi not_active IP Right Cessation
1987
- 1987-02-25 JP JP62042442A patent/JPS62205800A/ja active Granted
- 1987-02-26 NL NL8700483A patent/NL195097C/nl not_active IP Right Cessation
- 1987-02-26 DE DE19873706285 patent/DE3706285A1/de active Granted
- 1987-02-26 GB GB8704517A patent/GB2187283B/en not_active Expired - Lifetime
- 1987-02-26 KR KR870001680A patent/KR870008033A/ko not_active Withdrawn
- 1987-02-26 PT PT84368A patent/PT84368B/pt unknown
- 1987-02-26 IT IT19501/87A patent/IT1202581B/it active
- 1987-02-26 IS IS3197A patent/IS3197A7/is unknown
- 1987-02-26 LU LU86792A patent/LU86792A1/fr unknown
- 1987-02-26 HU HU87750A patent/HU201808B/hu unknown
- 1987-02-26 FR FR878702541A patent/FR2594849B1/fr not_active Expired - Lifetime
- 1987-02-26 DK DK198700993A patent/DK174784B1/da not_active IP Right Cessation
- 1987-02-26 CA CA000530691A patent/CA1287558C/fr not_active Expired - Lifetime
- 1987-02-26 ZA ZA871401A patent/ZA871401B/xx unknown
- 1987-02-26 NO NO870794A patent/NO175380C/no unknown
- 1987-02-26 ES ES08700776A patent/ES2061411A6/es not_active Expired - Fee Related
- 1987-02-26 SE SE8700821A patent/SE468816B/sv not_active IP Right Cessation
- 1987-02-26 AT AT431/87A patent/AT393511B/de not_active IP Right Cessation
- 1987-02-26 AU AU69275/87A patent/AU603562B2/en not_active Expired
- 1987-02-26 IE IE49687A patent/IE66904B1/en not_active IP Right Cessation
- 1987-02-26 CH CH756/87A patent/CH675593A5/de not_active IP Right Cessation
- 1987-02-26 NZ NZ219421A patent/NZ219421A/xx unknown
- 1987-02-26 BE BE8700177A patent/BE1001168A4/fr not_active IP Right Cessation
- 1987-02-27 IL IL81695A patent/IL81695A/xx not_active IP Right Cessation
- 1987-02-27 DD DD87300286A patent/DD270383A5/de unknown

Also Published As

Publication number	Publication date
SE468816B (sv)	1993-03-22
HU201808B (en)	1990-12-28
LU86792A1 (fr)	1987-07-24
IE66904B1 (en)	1996-02-07
JPH0561920B2 (fr)	1993-09-07
ATA43187A (de)	1991-04-15
FR2594849A1 (fr)	1987-08-28
IL81695A (en)	1991-04-15
IS3197A7 (is)	1987-08-28
GB8704517D0 (en)	1987-04-01
IE870496L (en)	1987-08-27
DK99387A (da)	1987-08-28
DK99387D0 (da)	1987-02-26
FR2594849B1 (fr)	1990-04-20
SE8700821D0 (sv)	1987-02-26
NL195097C (nl)	2004-03-17
AT393511B (de)	1991-11-11
AU6927587A (en)	1987-09-03
FI860836A0 (fi)	1986-02-27
SE8700821L (sv)	1987-08-28
ZA871401B (en)	1987-10-28
KR870008033A (ko)	1987-09-23
DE3706285A1 (de)	1987-11-12
GB2187283A (en)	1987-09-03
DE3706285C2 (fr)	1993-02-04
IL81695A0 (en)	1987-09-16
IT1202581B (it)	1989-02-09
FI76119B (fi)	1988-05-31
IT8719501A0 (it)	1987-02-26
NO870794L (no)	1987-08-28
HUT43647A (en)	1987-11-30
PT84368A (en)	1987-03-01
NO175380C (no)	1994-10-05
BE1001168A4 (fr)	1989-08-08
DK174784B1 (da)	2003-11-10
PT84368B (pt)	1989-10-04
NO870794D0 (no)	1987-02-26
ES2061411A6 (es)	1994-12-01
NL8700483A (nl)	1987-09-16
DD270383A5 (de)	1989-07-26
AU603562B2 (en)	1990-11-22
NZ219421A (en)	1988-11-29
FI860836L (fi)	1987-08-28
JPS62205800A (ja)	1987-09-10
CA1287558C (fr)	1991-08-13
FI76119C (fi)	1988-09-09
GB2187283B (en)	1990-05-30
NO175380B (no)	1994-06-27

Legal Events

Date	Code	Title	Description
1996-06-28	PUE	Assignment	Owner name: ORION-YHTYMAE OY TRANSFER- SANGTEC MEDICAL AB
2001-10-15	NV	New agent	Representative=s name: E. BLUM & CO. PATENTANWAELTE
2001-10-15	PUE	Assignment	Owner name: SANGTEC MEDICAL AB TRANSFER- SANGTEC MOLECULAR DIA
2007-03-30	PL	Patent ceased

Publication	Publication Date	Title
AT393511B (de)	1991-11-11	Verfahren zur quantitativen bestimmung von nucleinsaeure-molekuelen und reagenziensatz hierfuer
DE68929299T2 (de)	2001-12-06	Multiple genomische DNA-Verstärkung zum Nachweis einer Deletion
DE60314236T2 (de)	2008-02-14	Verfahren zur diagnose und therapie von schizophrenie
DE68916693T2 (de)	1994-11-03	Molekular-Diagnose von Alzheimer-Krankheit.
DE69527951T2 (de)	2003-04-24	Ein in-vivo genexpressions-system
DE69305662T2 (de)	1997-02-27	Brett-stabiles Produkt und Verfahren zur Isolierung der RNA, DNA und Proteine
DE3855064T2 (de)	1996-08-29	Selektive Amplifikation von Oligonukleotiden-Zielsequenzen
DE69233285T2 (de)	2004-11-25	Quantifikation von Nukleinsäuren
DE69434314T2 (de)	2006-03-30	Polymorphismus von mononukleotiden und ihre verwendung in der genanalyse
DE68909514T2 (de)	1994-01-20	Verfahren zur gleichzeitigen Bestimmung von DNS-Sequenzvariationen von zahlreichen Stellen und ein Satz dafür.
EP0438512B1 (fr)	1997-12-29	Procede pour l'analyse de polymorphismes longitudinaux dans des regions d'adn
DE68927059T3 (de)	2001-05-10	In-situ-unterdrückungs-hybridisierung und verwendungen
DE69003477T2 (de)	1994-01-27	Verfahren zum Nachweis von Nucleinsäuren.
DE69133135T2 (de)	2003-06-18	Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
EP0714987A2 (fr)	1996-06-05	Procédé pour quantifier d'ADN génomiques
DE60031320T2 (de)	2007-08-30	Verfahren zur Erfassung von Antisense-Oligonucleotiden und Peptidnucleinsäuren
EP0303925B1 (fr)	1995-06-07	Séquence très répressible pour le contrôle de l'expression
DE4225569A1 (de)	1994-02-10	Neue Sonde zur Tumordiagnostik oder Tumortherapie
DE69814622T2 (de)	2004-02-26	Eine apc-mutation, die mit familiärem dickdarmkrebs bei ashkenazi-juden einhergeht
AT409383B (de)	2002-07-25	Verfahren zur detektion und quantifizierung von nukleinsäuren in einer probe
DE69330604T2 (de)	2002-07-04	Verfahren und system zur molekularbiologischen diagnose
DE3789883T2 (de)	1994-10-06	Nukleare faktoren, die mit der regulierung der transkription assoziiert sind.
DE60013410T2 (de)	2005-09-15	Verfahren zur analyse der genexpressions-frequenz
DE69324129T2 (de)	1999-09-16	Verfahren für die verringerung von falschen positiven signalen in einem rns amplifikationssystem
EP0620439A2 (fr)	1994-10-19	Méthode de détermination de liaison entre des facteurs de transcription et des acides nucléiques